Angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker treatment and haemodynamic factors are associated with increased cardiac mRNA expression of angiotensin-converting enzyme 2 in patients with cardiovascular disease by Lebek, Simon et al.
European Journal of Heart Failure (2020) RESEARCH ARTICLE
doi:10.1002/ejhf.2020
Angiotensin-converting enzyme
inhibitor/angiotensin II receptor blocker
treatment and haemodynamic factors are
associated with increased cardiac mRNA
expression of angiotensin-converting enzyme
2 in patients with cardiovascular disease
Simon Lebek1, Maria Tafelmeier1, Rebecca Messmann1, Zdenek Provaznik2,
Christof Schmid2, Lars S. Maier1, Christoph Birner3, Michael Arzt1,
and Stefan Wagner1*
1Department of Internal Medicine II, University Hospital Regensburg, Regensburg, Germany; 2Department of Cardiothoracic Surgery, University Hospital Regensburg,
Regensburg, Germany; and 3Department of Internal Medicine I, Klinikum St. Marien, Amberg, Germany
Received 24 June 2020; revised 30 September 2020; accepted 1 October 2020
Aims Coronavirus disease 2019 (COVID-19) is a widespread pandemic with an increased morbidity and mortality, especially
for patients with cardiovascular diseases. Angiotensin-converting enzyme 2 (ACE2) has been identified as necessary
cell entry point for SARS-CoV-2. Previous animal studies have demonstrated an increased ACE2 expression following
treatment with either angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARB) that
have led to a massive precariousness regarding the optimal cardiovascular therapy during this pandemic.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Methods
and results
We have measured ACE2 mRNA expression using real-time quantitative polymerase chain reaction in atrial biopsies
of 81 patients undergoing coronary artery bypass grafting and we compared 62 patients that received ACEi/ARB vs.
19 patients that were not ACEi/ARB-treated. We found atrial ACE2 mRNA expression to be significantly increased
in patients treated with an ACEi or an ARB, independent of potential confounding comorbidities. Interestingly, the
cardiac ACE2 mRNA expression correlated significantly with the expression in white blood cells of 22 patients
encouraging further evaluation if the latter may be used as a surrogate for the former. Similarly, analysis of 18
ventricular biopsies revealed a significant and independent increase in ACE2 mRNA expression in patients with
end-stage heart failure that were treated with ACEi/ARB. On the other hand, cardiac unloading with a left ventricular
assist device significantly reduced ventricular ACE2 mRNA expression.
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Conclusion Treatment with ACEi/ARB is independently associated with an increased myocardial ACE2 mRNA expression in
patients with coronary artery disease and in patients with end-stage heart failure. Further trials are needed to
test whether this association is deleterious for patients with COVID-19, or possibly protective. Nevertheless,
haemodynamic factors seem to be equally important for regulation of cardiac ACE2 mRNA expression.
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Introduction
Coronavirus disease 2019 (COVID-19) is a widespread pandemic
with an extensive morbidity and a mortality with up to 10% in
certain countries.1–5 Besides typical symptoms like fever, cough
or dyspnoea, COVID-19 is also associated with severe cardiovas-
cular complications, like acute myocardial injury, arrhythmias, or
thrombosis.1–5 Importantly, patients with cardiovascular diseases
are at increased risk for COVID-19 infection and exhibit a five-fold
increased COVID-19-associated mortality.1–6
COVID-19 is caused by the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) that is known to use cell-bound
angiotensin-converting enzyme 2 (ACE2) for cell entry.7 Intrigu-
ingly, recent investigations have shown that both treatment with
angiotensin-converting enzyme inhibitor (ACEi) or angiotensin II
receptor blocker (ARB) leads to an increase in cardiac ACE2
mRNA expression in rats.8 Moreover, treatment with the ARB
olmesartan seems to upregulate urinary ACE2 secretion in hyper-
tensive patients, proposing that upregulation of ACE2 may also be
present in humans.9 Recently, Nicin et al.10 have demonstrated an
increased myocardial ACE2 mRNA expression in patients treated
with an ACEi, but the number of investigated patients was very low
and important confounding comorbidities have not been investi-
gated. On the other hand, in a large scale cross-sectional study
of heart failure (HF) patients, plasma ACE2 protein levels did
not correlate with ACEi/ARB treatment.11 Although the latter
is more functionally relevant, the mechanisms of ACE2 protein
plasma shedding are complex and may be differentially affected
by HF, angiotensin II signalling and drug treatment.12 Moreover, it
is unclear if non-membrane bound plasma ACE2 would be rele-
vant for SARS-CoV-2 cell entry and damage. The binding of solu-
ble ACE2 protein to SARS-CoV-2 in plasma might result in some
level of reduction of viral particles and even block early stages
of SARS-CoV-2 infections, at least in engineered human tissue.13
On the other hand, soluble ACE2-SARS-CoV-2 fusion particles
may also be dangerous since they can interact with endothe-
lial membrane-bound ACE2 leading to endothelial damage. For
instance, epidemiological studies suggest that COVID-19 patients
with cardiovascular diseases and high plasma ACE2 levels have
a more than five times increased mortality rate possibly due to
endothelial morbidities with thrombotic sequelae.1,3–5,14
Despite overwhelming evidence that ACEi/ARB treatment
reduces morbidity and mortality in cardiovascular patients, these
recent concerns about a potential increase in the susceptibility for
SARS-CoV-2 infection with potentially deleterious outcome have
already encouraged physicians to withhold ACEi/ARB treatment
for patients with cardiovascular disease, despite a complete lack
of evidence.6,15
The present study adds novel data about the impact of ACEi/ARB
treatment on cardiac and white blood cellular ACE2 mRNA
expression in high-risk patients undergoing heart surgery.
Methods
All methods are described in detail in the online supplementary mate-



















































































.. of patients enrolled in the observational trial CONSIDER-AF between
May 2016 and August 2018 (online supplementary Figure S1). We
measured ACE2 mRNA expression using real-time quantitative poly-
merase chain reaction in right atrial appendage biopsies of 81 patients
and in white blood cells (WBCs) of 22 patients undergoing elective
coronary artery bypass grafting. Additionally, we measured ventricular
ACE2 mRNA expression of 18 patients with end-stage HF before and
after cardiac unloading with a left ventricular assist device (LVAD).
Differences between groups were compared using t-test for normally
distributed continuous variables, the Wilcoxon–Mann–Whitney test
for non-normally distributed continuous variables and the Chi-square
test of independence for categorical variables. If the expected frequen-
cies during contingency analysis were low, Fisher’s exact test was used.
Univariable regression analyses were conducted with predisposing risk
factors as independent variables and with myocardial ACE2 mRNA
expression as a dependent variable. To test for interactions, multivari-
able regression models, including selected independent variables, were
calculated. A two-sided P-value ≤0.05 was considered statistically
significant for all analyses.
Results
Baseline characteristics of patients that
donated atrial myocardium
Eighty-one patients undergoing elective coronary artery bypass
grafting donated their right atrial appendage biopsy and were
included in the study (Table 1). This cohort was stratified according
to their medical treatment into patients treated with either ACEi
or ARB (n = 62: 46 ACEi, 16 ARB), and patients without ACEi/ARB
treatment (n =19). The patient cohorts did not differ in age,
showed equal gender distribution, body mass index (BMI), New
York Heart Association (NYHA) status and heart function. How-
ever, arterial hypertension and hyperlipidaemia were significantly
more common in patients treated with ACEi/ARB (Table 1). Con-
sistently, ACEi/ARB-treated patients were more frequently treated
with thiazide diuretics and statins (Table 1).
Atrial angiotensin-converting enzyme 2
mRNA expression is increased
in patients treated
with angiotensin-converting enzyme
inhibitor/angiotensin II receptor blocker
Figure 1 shows the frequency distribution of atrial ACE2 mRNA
expression (normalized to β-actin) for the total patient cohort
(Figure 1A) and for the patient subgroups stratified according to
ACEi/ARB treatment (Figure 1B). In addition, scatter plots stratified
according to treatment with ACEi/ARB are presented (Figure 1B).
Importantly, compared to untreated patients, there was a signif-
icant increase in atrial ACE2 mRNA expression about 1.41-fold
from (in % of β-actin) 0.37± 0.16 to 0.52± 0.32 in patients treated
with ACEi/ARB (P = 0.009; Figure 1B). This corresponds to an effect
size (Cohen’s d) of 0.58, which represents a medium effect size
with potential biological significance. This increase was consistent
across both patients treated with either ACEi or ARB although
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Table 1 Baseline characteristics of patients undergoing elective coronary artery bypass grafting
Total cohort (n = 81) No ACEi/ARB (n = 19) ACEi/ARB (n = 62) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age, years, mean± SD 67.0± 8.6 68.9± 7.5 66.5± 8.9 0.27T
Male sex, n (%) 72 (89) 16 (84) 56 (90) 0.46Chi
BMI, kg/m2, mean± SD 28.1± 4.3 28.4± 3.8 28.0± 4.5 0.72T
Cardiovascular risk factors
Arterial hypertension, n (%) 69 (85) 13 (68) 56 (90) 0.02Chi
Systolic blood pressure, mmHg, mean± SD 137.9± 20.6 137.6± 21.7 138.0± 20.4 0.94T
Diastolic blood pressure, mmHg, mean± SD 77.7±11.1 78.4±11.1 77.5±11.2 0.74T
Smoker, n (%) 52 (64) 15 (79) 37 (60) 0.13Chi
Previous smoker 38 (47) 12 (63) 26 (42) 0.10Chi
Current smoker 14 (17) 3 (16) 11 (18) 0.84Chi
Diabetes mellitus, n (%) 21 (26) 7 (37) 14 (23) 0.21Chi
Hyperlipidaemia, n (%) 52 (64) 7 (37) 45 (73) 0.004Chi
Atrial fibrillation, n (%) 9 (11) 3 (16) 6 (10) 0.46Chi
History of TIA or stroke, n (%) 8 (10) 3 (16) 5 (8) 0.32Chi
Heart function
Heart failurea, n (%) 30 (37) 7 (37) 23 (37) 0.98Chi
NYHA functional classb, n (%)
I 14 (17) 4 (21) 10 (16) 0.62Chi
II 16 (20) 3 (16) 13 (21) 0.62Chi
III–IV 0 (0) 0 (0) 0 (0) 1.00Chi
NT-proBNP, pg/mL, median (IQR) 259 (87–705) 166 (73–881) 259 (99–705) 0.85W
LVEF, %, mean± SD 56.5± 8.6 57.2± 7.0 56.4± 9.1 0.72T
LVEF <50%, n (%) 11 (14) 2 (11) 9 (15) 0.66Chi
LAVI, mL/m2, mean± SD 42.4±16.3 45.3± 5.3 41.6± 18.6 0.74T
LVMI, g/m2, mean± SD 83.5± 26.4 92.8± 40.4 81.0± 22.0 0.34T
Diastolic dysfunction, n (%) 38 (47) 8 (42) 30 (48) 0.77Chi
GFR, mL/min, mean± SD 75.6± 21.8 75.8±17.7 75.6± 23.0 0.98T
Medical treatment, n (%)
ACEi 46 (57) 0 (0) 46 (74) <0.001Chi
ARB 16 (20) 0 (0) 16 (26) 0.01Chi
CCB 26 (32) 4 (21) 22 (35) 0.24Chi
MRA 3 (4) 0 (0) 3 (5) 0.33Chi
Beta-blockers 56 (69) 12 (63) 44 (71) 0.52Chi
Loop diuretics 14 (17) 3 (16) 11 (18) 0.84Chi
Thiazide diuretics 21 (26) 1 (5) 20 (32) 0.02Chi
Statins 61 (75) 11 (58) 50 (81) 0.04Chi
Note: Bold value shown comparison is statistically significant.
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; CCB, calcium channel blocker; Chi, Chi-square test;
GFR, glomerular filtration rate; IQR, interquartile range; LAVI, left atrial volume index; LVEF, left ventricular ejection fraction; LVMI, left ventricular mass index; MRA,
mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro brain natriuretic peptide; NYHA, New York Heart Association; SD, standard deviation; T, Student’s
t-test; TIA, transient ischaemic attack; W, Wilcoxon rank-sum test.
aRequirement of symptoms and LVEF <40% or elevated NT-proBNP levels and either left ventricular hypertrophy (left ventricular mass index ≥115 g/m2 for male, ≥95 g/m2
for female patients), left atrial enlargement (LAVI >34 mL/m2), or diastolic dysfunction.
bIf heart failure was diagnosed.
the latter did not reach statistical significance (online supplemen-
tary Figure S3A).
Since ACE2 can also be found in WBCs and may be used as
a biomarker for clinical routine, we also measured ACE2 mRNA
expression in WBCs of a subgroup of 22 patients. The frequency
distribution plot (online supplementary Figure S2A) indicates a
much lower absolute expression level compared to the atrium.
On the other hand, there was a significant correlation in the ACE2
mRNA expression level between atrium and the corresponding
blood (R2 = 0.26, P = 0.02; online supplementary Figure S2B)
with higher ACE2 mRNA levels in patients treated with ACEi/ARB

















.. The increase in atrial
angiotensin-converting enzyme 2 mRNA
expression was independent of clinical
covariates
The lack of randomization implies that heterogeneities in the
patient cohorts may substantially confound our results. Therefore,
we performed multiple univariate logistic and linear regression
analysis of atrial ACE2 mRNA expression. We defined an ACE2
mRNA expression >0.5478 as increased, which corresponds to
the upper 95% confidence interval derived from the frequency
distribution of the total cohort (Figure 1A). In both the logistic
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Atrial angiotensin-converting enzyme 2 (ACE2)
mRNA expression in patients treated with angiotensin-converting
enzyme inhibitor/angiotensin II receptor blocker (ACEi/ARB). (A)
Frequency distribution of ACE2 expression. Vertical lines indicate
median and upper 95% confidence interval (CI). (B) Scatter and
violin plots of atrial ACE2 mRNA expression stratified by patients
treated with either ACEi/ARB or not and the corresponding
frequency distribution underneath.
and linear models, cardiac ACE2 mRNA expression was increased
in patients treated with ACEi/ARB, but only in the linear model
this increase reached statistical significance (P = 0.052 vs. P = 0.04;
Figure 2 and online supplementary Table S3). Intriguingly, presence
of HF and elevated N-terminal pro brain natriuretic peptide
(NT-proBNP) levels were associated with increased ACE2 mRNA
expression levels in both logistic and linear regression models
(Figure 2 and online supplementary Table S3). On the other hand,
there was a significant negative association of BMI with increased
atrial ACE2 mRNA expression (Figure 2 and online supplementary
Table S3). Importantly, neither the presence of arterial hyper-
tension nor hyperlipidaemia or pharmacological treatment with
mineralocorticoid receptor antagonists (MRAs), thiazides or
statins affected atrial ACE2 mRNA expression (Figure 2 and online



















































































.. To further analyse the impact of potential confounders, a multi-
variate logistic and linear regression analysis was performed includ-
ing advanced age (age≥70 years), BMI, presence of HF, atrial fibril-
lation and history of transient ischaemic attack or stroke into the
model (Table 2 and online supplementary Table S3). Importantly, the
association of increased ACE2 mRNA expression with ACEi/ARB
treatment was independent of all analysed comorbidities suggest-
ing that there may be a mechanistic link. To further explore the
impact of ACEi/ARB treatment on ACE2 expression, subgroups
of patients were analysed for the mean difference in atrial ACE2
mRNA expression between patients treated with ACEi/ARB and
untreated patients by linear regression and weighting by sample
size. Figure 3 indicates that the impact of ACEi/ARB treatment on
ACE2 mRNA expression levels was maintained across all investi-
gated subgroups including older patients (age≥70 years), patients
with increased BMI, patients with arterial hypertension, hyperlipi-
daemia, diabetes mellitus, HF, or kidney disease.
Baseline characteristics of patients
with end-stage heart failure
Heart failure has been shown to be associated with an increased
ACE2 expression.16,17 Moreover, we have shown here a signifi-
cant association of HF and elevated NT-proBNP levels with atrial
ACE2 mRNA expression (Figure 2). On the other hand, only 37% of
coronary artery bypass graft patients presented with HF (Table 1)
and only 5% of patients had HF with reduced ejection fraction.
Therefore, we additionally analysed left ventricular ACE2 mRNA
expression in 18 patients with end-stage HF that were scheduled
for implantation of an LVAD and were later subjected to heart
transplantation. The baseline characteristics of these patients strat-
ified according to treatment with ACEi/ARB (n =12) vs. patients
without ACEi/ARB (n = 6) are shown in online supplementary Table
S1. The latter six HF patients were not treated with an ACEi/ARB
since they were either haemodynamically unstable (acute decom-
pensated HF or cardiogenic shock), or they suffered from severe
symptomatic hypotension. The mean duration on LVAD (about
300 days) was not different between groups. All patients were
middle-aged and both groups showed a similar gender distribution.
While there was no difference in the prevalence of arterial hyper-
tension, diabetes mellitus, or atrial fibrillation, ACEi/ARB-treated
patients were more frequently treated with MRAs (10/12 vs. 2/6;
online supplementary Table S1) and beta-blockers (11/12 vs. 2/6;
online supplementary Table S1).
Ventricular angiotensin-converting
enzyme 2 mRNA expression was
increased in heart failure patients
treated with angiotensin-converting
enzyme inhibitor/angiotensin II receptor
blocker
Figure 4 shows the frequency distribution of ventricu-
lar ACE2 mRNA expression (normalized to hypoxanthine
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Figure 2 Univariate logistic regression analysis for atrial angiotensin-converting enzyme 2 (ACE2) mRNA expression. Forest plot showing
odds ratio (OR) and 95% confidence interval (CI) derived from univariate logistic regression analysing the risk of increased atrial ACE2 mRNA
expression (>0.5478) for multiple clinical variables. ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker;
BMI, body mass index; CCB, calcium channel blocker; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist;
NT-proBNP, N-terminal pro brain natriuretic peptide; TIA, transient ischaemic attack. #Requirement of symptoms and LVEF <40% or elevated
NT-proBNP levels and either left ventricular hypertrophy (left ventricular mass index ≥115 g/m2 for male, ≥95 g/m2 for female patients), left
atrial enlargement (left atrial volume index >34 mL/m2), or diastolic dysfunction. ¶>300 pg/mL for patients without atrial fibrillation, >900 pg/mL
for patients with atrial fibrillation. §Glomerular filtration rate <60 mL/min.
Table 2 Multivariate logistic regression analysis for
factors that influence increased atrial
angiotensin-converting enzyme 2 mRNA expression
(n = 81)
OR (95% CI) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Multivariate model for increased
ACE2 mRNA expression
0.026
Treatment with ACEi/ARB 5.745 (1.047–31.533) 0.044
Age≥70 years 1.964 (0.640–6.024) 0.238
Male sex 0.844 (0.149–4.749) 0.847
BMI (kg/m2) 0.892 (0.769–1.034) 0.130
Heart failurea 2.327 (0.747–7.253) 0.145
Atrial fibrillation 2.647 (0.520–13.484) 0.241
History of TIA or stroke 0.794 (0.105–5.997) 0.823
Note: Bold value shown comparison is statistically significant.
Increased ACE2 mRNA expression was defined as >0.5478.
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI,
body mass index; CI, confidence interval; OR, odds ratio; TIA, transient ischaemic attack.
aRequirement of symptoms and left ventricular ejection fraction <40% or elevated N-terminal
pro brain natriuretic peptide levels and either left ventricular hypertrophy (left ventricular
mass index ≥115 g/m2 for male, ≥95 g/m2 for female patients), left atrial enlargement (left





























. ribosyltransferase) for patients subjected to LVAD implanta-
tion (Figure 4A). Importantly, at LVAD implantation, ventricular
ACE2 mRNA expression was approximately quadrupled in patients
that were treated with an ACEi/ARB inhibitor (to 198.5 ± 75.0%)
compared to patients without ACEi/ARB inhibition (44.7 ± 43.1%,
P = 0.0004; Figure 4B). This increase was consistent across both
patient groups treated with either ACEi or ARB (online supple-
mentary Figure S3B). Interestingly, we also observed a strong
trend towards an increased ACE2 mRNA expression in patients
treated with MRAs (P = 0.10) or beta-blockers (P = 0.08; online
supplementary Table S2).
To further analyse the clinical covariates that may influ-
ence ventricular ACE2 expression at LVAD implantation we
conducted a multivariate linear regression analysis accounting
for the treatment with ACEi/ARB, age, BMI, atrial fibrillation,
treatment with beta-blockers, treatment with MRAs, diabetes
mellitus, and the glomerular filtration rate (online supplementary
Table S2). Pre-existing treatment of patients with ACEi/ARB
was independently associated with increased ventricular ACE2
mRNA expression at LVAD implantation (P = 0.01 for ACEi/ARB
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 3 The effect of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker (ACEi/ARB) therapy on angiotensin-converting
enzyme 2 (ACE2) mRNA expression. The mean difference in ACE2 mRNA expression (and 95% confidence interval, CI) between patients
treated with ACEi/ARB vs. patients not treated is shown as forest plot. The mean difference was weighted by sample size (weighted mean
difference, WMD). BMI, body mass index; BNP, brain natriuretic peptide; Ca, calcium; TIA, transient ischaemic attack. #Requirement of
symptoms and left ventricular ejection fraction <40% or elevated N-terminal proBNP levels and either left ventricular hypertrophy (left
ventricular mass index ≥115 g/m2 for male, ≥95 g/m2 for female patients), left atrial enlargement (left atrial volume index >34 mL/m2), or
diastolic dysfunction. ¶>300 pg/mL for patients without atrial fibrillation, >900 pg/mL for patients with atrial fibrillation. §Glomerular filtration
rate <60 mL/min.
treatment, R2 = 0.72 and P = 0.04 for the whole multivariate
model; online supplementary Table S2).
Cardiac unloading by LVAD is known to induce structural,
molecular and genomic alterations in the heart that may also
affect ACE2 expression.18 Therefore, we measured ventricular








. of LVAD therapy at heart transplantation (Figure 4C and 4D).
Interestingly, there was a significant reduction in ventricular ACE2
mRNA expression upon LVAD treatment (Figure 4C) indicating that
ventricular ACE2 expression may be reduced by haemodynamic
improvement. Moreover, at heart transplantation, the ventricular
ACE2 mRNA expression was reduced by LVAD therapy to such an
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 4 Ventricular angiotensin-converting enzyme 2 (ACE2) mRNA expression in failing hearts. (A) Frequency distribution of ventricular
ACE2 mRNA expression at left ventricular assist device (LVAD) implantation. (B) Scatter and violin plots of ventricular ACE2 mRNA expression
stratified by patients treated with either angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker (ACEi/ARB) or not. (C)
Spaghetti plot of ventricular ACE2 mRNA expression at LVAD implantation and at heart transplantation (about 300 days later). (D) Scatter and
violin plots of ACE2 mRNA expression at heart transplantation. HPRT, hypoxanthine ribosyltransferase.
extent that there was no detectable difference between patients
treated with ACEi/ARB and untreated patients (Figure 4D).
Discussion
In this study we investigated the effect of ACEi/ARB treatment on
cardiac mRNA expression of ACE2, the cell entry mechanism of
SARS-CoV-2, in a larger scale cohort of patients undergoing heart
surgery and in patients with end-stage HF. Interestingly, this is the
first study demonstrating that treatment with ACEi/ARB was signif-
icantly and independently associated with increased cardiac ACE2
mRNA expression in patients at high risk of severe COVID-19. In
addition, we found no difference between ACEi or ARB treatment
on ACE2 mRNA expression. On the other hand, we showed
that in patients with end-stage HF, cardiac unloading by LVAD
























. expression abolishing the impact of ACEi/ARB treatment. This sug-
gests that – in addition to ACEi/ARB treatment – haemodynamic
factors or cardiovascular diseases may also be important for the
regulation of cardiac ACE2 expression. This is in accordance with
observational and retrospective clinical trials showing no harm by
continuing ACEi/ARB treatment in patients with COVID-19 and
cardiovascular disease.19–21
Potential regulation of SARS-CoV-2 cell
entry mechanism angiotensin-converting
enzyme 2 by angiotensin-converting
enzyme/angiotensin II receptor blocker
treatment
Since December 2019, COVID-19 is spreading from Wuhan,
China, all over the world with dramatic infection, morbidity and
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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mortality rates.1–5 It is induced by SARS-CoV-2, which uses ACE2
for cell entry.7 COVID-19 is frequently associated with severe
cardiovascular complications and cardiovascular patients suffering
from COVID-19 have a dramatically increased mortality rate with
an increased risk of life-threatening arrhythmias and myocardial
injury.1–6 A recent study has demonstrated that 56% of COVID-19
patients with initial chest pain and ST-segment elevation had
non-coronary myocardial injury, indicating that direct effects of
SARS-CoV-2 (e.g. potentially via ACE2) on the myocardium may
be important.22
Angiotensin-converting enzyme 2 is a key enzyme that coun-
teracts the renin–angiotensin system by degrading angiotensin
I to angiotensin-(1–9) and angiotensin II to angiotensin-(1–7),
thereby alleviating the detrimental angiotensin signalling.14,17 In
fact, a protective effect of ACE2 in the context of severe
inflammation-dependent lung injury has been shown by multiple
studies.23–25 Interestingly, the beneficial effect may be not lim-
ited to membrane-bound ACE2 since administration of recom-
binant human ACE2 has been proven beneficial in improving
lung pathologies.23–25 Therefore, the fact that ACEi/ARB treat-
ment leads to a significant and independent increase in myocardial
ACE2 mRNA expression may even be beneficial for patients with
COVID-19 infection. In accordance, there are already a few studies
showing that ACEi/ARB treatment does not increase the risk for
SARS-CoV-2 infection or even improve the outcome if COVID-19
develops.19,26,27
Recently, several animal studies have suggested that ACE2
expression may be upregulated by ACEi/ARB inhibition. Ferrario
et al.8 have shown that treatment of rats with lisinopril or losar-
tan (only eight rats each) resulted in increased cardiac ACE2
mRNA expression. Other animal studies have suggested an upreg-
ulation of ACE2 by ACEi/ARB treatment also in murine kidney
arterioles28 and in the aorta of hypertensive rats.29 On the other
hand, Burchill and colleagues did not detect a change in car-
diac ACE2 mRNA expression following ACEi or ARB treatment
in rats.30
In contrast to animal data, very few studies have addressed
ACE2 expression in humans. In a Japanese study comparing 101
healthy controls with 100 hypertensive patients under antihy-
pertensive therapy, only olmesartan treatment (13 patients) was
associated with increased urinary ACE2 secretion, while neither
enalapril, losartan, candesartan, valsartan nor telmisartan showed
that effect.9 In this context, a large scale observational study has
recently shown that plasma ACE2 protein levels do not corre-
late with existing ACEi/ARB therapy in HF patients.11 The rele-
vance of these finding, however, is unclear, since urinary or plasma
ACE2 level do not necessarily correlate with membranous ACE2
expression – and only the latter is relevant for SARS-CoV-2 cell
entry.7,17 Most recently, Nicin et al.10 demonstrated an increased
ACE2 mRNA expression in patients treated with ACEi com-
pared to patients with an ARB. Unfortunately, this study was
dramatically limited due to a very small sample size of four vs.
two patients, respectively.10 In addition, they have not exam-
ined the impact of potentially cofounding patients comorbidities





















































































enzyme/angiotensin II receptor blocker
treatment increased cardiac
angiotensin-converting enzyme 2 mRNA
expression in high-risk patients
To improve our understanding of regulation of ACE2 expression,
we have investigated cardiac ACE2 mRNA expression in a high-risk
patient population. We show here that ACE2 mRNA expression
was increased in a large scale cohort of 81 patients undergo-
ing heart surgery and in patients with end-stage HF that were
treated with ACEi/ARB. Importantly, we also found several other
patient characteristics that are associated with differential ACE2
mRNA expression, like obesity or HF. Accounting for that, we con-
ducted a multivariate logistic regression analysis showing that treat-
ment with ACEi/ARB was independently associated with increased
myocardial ACE2 mRNA expression. Interestingly, we observed a
strong but non-significant trend towards increased ACE2 mRNA
expression in WBCs of patients treated with ACEi/ARB. More-
over, there was a significant correlation of cardiac and white blood
cellular ACE2 mRNA expression. This may be in contrast to
plasma ACE2 levels that are shed from various cell types including
endothelial cells into the plasma. Plasma ACE2 levels have not been
shown to correlate with ACEi/ARB treatment.11 Nevertheless, this
finding may offer a starting point for future studies investigating
white blood cellular ACE2 expression as a potential biomarker for
ACE2 expression in other organs and its biological impact, e.g. in
lungs of COVID-19 patients.
Importantly, we found the presence of HF as well as elevated
NT-proBNP levels to be significantly associated with increased
atrial ACE2 mRNA expression (Figure 2), which is in accordance
with previous studies.16,17 To further investigate ACE2 regulation
in end-stage HF, we analysed ventricular ACE2 mRNA expression
in 18 patients before and after cardiac unloading with LVAD ther-
apy. Intriguingly, we were able to detect an increased cardiac ACE2
mRNA expression in end-stage HF patients treated with ACEi/ARB
therapy. Sama et al.11 reported that patients with HF that were
treated with MRAs exhibited increased plasma ACE2 protein lev-
els. Therefore, we included treatment with MRAs in multivariate
regression analysis showing a strong trend for increased ACE2
mRNA expression in patients treated with MRAs (P = 0.10; online
supplementary Table S2). However, when this regression analysis
was corrected for multiple covariates including ACEi/ARB treat-
ment, the association between MRA treatment and ACE2 mRNA
expression levels was completely abolished (online supplementary
Table S2). In contrast, the association between ACEi/ARB treat-
ment and ACE2 mRNA expression was maintained in multivari-
ate regression analysis with similar slope and level of significance
(online supplementary Table S2). Therefore, it remains unclear
if MRA treatment alone without accompanying ACEi/ARB treat-
ment is able to influence cardiac ACE2 expression levels. At first
glance, our data appear to be in contrast to Sama et al.,11 who
showed a significant increase in ACE2 plasma protein levels in
HF patients treated with MRA but reduced ACE2 plasma pro-
tein levels in patients treated with ACEi/ARB even after correction
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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for concomitant drug treatment. A possible explanation for the
discrepancies may arise from the methodological differences across
the studies. Sama et al.11 measured ACE2 protein in plasma
and not in myocardium. Plasma ACE2 proteins are derived from
proteolytic shedding of membrane-bound ACE2 and are origi-
nated from different tissue sources (endothelium, myocardium,
etc.). It has been shown that angiotensin II-mediated activation of
ADAM-17 stimulates the proteolytic shedding of ACE2 into the
plasma.12 Thus, inhibition of angiotensin II-mediated activation of
ADAM-17 by ACEi/ARB treatment reduces ACE2 plasma shed-
ding, which would result in reduced plasma ACE2 but increased
tissue ACE2 levels. MRAs, on the other hand, directly act on ACE2
transcription leading to an increase in ACE2 mRNA and a sec-
ondary increase in ACE2 protein both membrane-bound and shed
into plasma.14 Therefore, our study is in accordance with Sama
et al. We suggest here that ACEi/ARB treatment increases car-
diac ACE2 levels also by stimulation of cardiac ACE2 transcrip-
tion possibly by reducing circulating aldosterone levels. However,
futures studies are required to exactly identify the mechanism of
ACEi/ARB-dependent transcriptional regulation of ACE2 and its
impact on cardiac membrane-bound ACE2 protein levels.
Regulation of angiotensin-converting
enzyme 2 mRNA expression by cardiac
unloading with left ventricular assist
device
We show here that cardiac ACE2 mRNA expression was dramat-
ically reduced after LVAD implantation, indicating that improved
haemodynamics following cardiac unloading may impact cardiac
ACE2 expression. A part of this regulation may in fact result from
altered levels of renin, angiotensin II and aldosterone. Interestingly,
LVAD support, by normalizing blood pressure, has been shown
to lower renin and aldosterone levels. However, in apparent con-
trast, cardiac angiotensin I and II levels were increased 5–10-fold
post-LVAD implantation.18 As stated above, angiotensin II stim-
ulates the proteolytic shedding of ACE2 into the plasma, which
would reduce cardiac membrane-bound ACE2.12 Aldosterone,
on the other hand, increases ACE2 transcription. Therefore, the
unique combination of reduced aldosterone but increased cardiac
angiotensin II levels after cardiac unloading may be responsible for
the observed reduction in cardiac ACE2 expression. Importantly,
considering that 14 of 18 patients had been treated with ACEi/ARB,
the cardiac increase in angiotensin II upon LVAD must have been
dramatic exceeding the impact of ACEi/ARB treatment on cardiac
ACE2 levels.
Limitations
While ACE2 is the main cell entry mechanism for SARS-CoV-2,7
it is important to note that we have not measured directly the
susceptibly for an infection or for a deleterious disease progression
in vivo.
Another limitation originates from the methodology of the



















































































.. expression. An impaired translation into the functional relevant
protein, an altered subcellular protein localization or an increased
protein degradation may hamper the transferability of mRNA
data to protein levels. Also, we have not differentiated mRNA
expression between cardiac cell types. However, since more than
90% of cardiac tissue consists of cardiomyocytes, this issue may be
less important.
The analysis of WBC ACE2 mRNA expression may also be
subject to limitation. While we did find a significant correlation
between cardiac and WBC ACE2 mRNA expression, we did not
observe a significant increase in WBC ACE2 mRNA expression
in patients treated with ACEi/ARB despite an almost doubled
mean expression (online supplementary Figure S2C). Although
we cannot exclude a mechanistic explanation, we assume that the
small number of patients – especially the relatively low number
of patients without ACEi/ARB treatment (n = 5) – precludes
statistical significance for this comparison between two patient
groups. In contrast to the comparison between patients treated
with or without ACEi/ARB, the correlation analysis of WBC ACE2
mRNA expression with cardiac ACE2 mRNA expression included
all 22 patients into a linear model. The increased power of this type
of analysis may explain why we were able to detect a significant
correlation of cardiac and blood ACE2 mRNA expression.
This imbalance in the number of patients treated with or
without ACEi/ARB may also apply to the main study cohort.
From the 81 patients analysed, there were only 19 patients not
treated with ACEi/ARB. Despite our multiple attempts to control
for confounders, imbalances in patient characteristics cannot be
completely eliminated.
Conclusion
Treatment with ACEi/ARB was associated with increased cardiac
ACE2 mRNA expression independent of many comorbidities. In
end-stage HF patients, ACE2 mRNA expression was dramatically
affected by ventricular unloading suggesting that haemodynamic
factors may also be pivotal for regulation of cardiac ACE2 expres-
sion. Given the dramatic clinical benefit evoked by ACEi/ARB ther-
apy especially in high-risk patients with HF and the potential strong
influence of other comorbidities on ACE2 expression, treatment
with ACEi/ARB should not be withheld in these high-risk patient
populations, at least not until data from randomized clinical trials
prove otherwise.
Supplementary Information
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
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